{"organizations": [], "uuid": "99fb4a2b469fc20f532857e09e2d2566a30b319e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180508.html", "section_title": "Archive News &amp; Video for Tuesday, 08 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-jazz-pharmaceuticals-reports-q1-ad/brief-jazz-pharmaceuticals-reports-q1-adjusted-earnings-per-share-2-98-idUSASC0A0NI", "country": "US", "domain_rank": 408, "title": "BRIEF-Jazz Pharmaceuticals Reports Q1 Adjusted Earnings Per Share $2.98", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.041, "site_type": "news", "published": "2018-05-09T04:35:00.000+03:00", "replies_count": 0, "uuid": "99fb4a2b469fc20f532857e09e2d2566a30b319e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-jazz-pharmaceuticals-reports-q1-ad/brief-jazz-pharmaceuticals-reports-q1-adjusted-earnings-per-share-2-98-idUSASC0A0NI", "ord_in_thread": 0, "title": "BRIEF-Jazz Pharmaceuticals Reports Q1 Adjusted Earnings Per Share $2.98", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-jazz pharmaceuticals", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "jazz pharmaceuticals plc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8 (Reuters) - Jazz Pharmaceuticals PLC:\n* JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 GAAP EARNINGS PER SHARE $0.75 * Q1 REVENUE $445 MILLION VERSUS I/B/E/S VIEW $434.2 MILLION\n* Q1 EARNINGS PER SHARE VIEW $2.78 â€” THOMSON REUTERS I/B/E/S\n* UPDATED FINANCIAL GUIDANCE FOR 2018. * SEES FULL YEAR 2018 GAAP NET INCOME PER DILUTED SHARE $6.60-$7.70\n* SEES FULL YEAR 2018 NON-GAAP ADJUSTED NET INCOME PER DILUTED SHARE $12.75-$13.25\n* SEES FULL YEAR 2018 TOTAL NET PRODUCT SALES $1,865 MILLION -$1,910 MILLION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-09T04:35:00.000+03:00", "crawled": "2018-05-09T12:48:45.009+03:00", "highlightTitle": ""}